SCHEMBL1179422

SCHEMBL1179422

CCN(CC)c1nc(C)cc(-c2noc(-c3cc(C)nc(C)c3)n2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 4/20 0.39
TP53 P04637 5/20 0.39
PKM P14618 5/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
S1PR1 P21453 4/20 0.38
NPC1 O15118 5/20 0.37
RAB9A P51151 4/20 0.37
MAPT P10636 3/20 0.37
ALDH1A1 P00352 3/20 0.37
TSHR P16473 2/20 0.37
TDP1 Q9NUW8 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
KDM4E B2RXH2 2/20 0.36
GAA P10253 1/20 0.35
LMNA P02545 1/20 0.35
KLF5 Q13887 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSD17B10 Q99714 1/20 0.35
S1PR3 Q99500 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1179054 0.92 GRM5 (0.36) GRM5TP53PKMMEN1KMT2A
SCHEMBL1179159 0.89 S1PR1 (0.38) S1PR1NPC1RAB9AMAPTALDH1A1
SCHEMBL1180194 0.84 CRHR1 (0.37) GRM5TP53PKMMEN1KMT2A
SCHEMBL1179435 0.82 S1PR1 (0.36) S1PR1NPC1RAB9AMAPTALDH1A1
SCHEMBL1180310 0.79 S1PR1 (0.40) GRM5TP53PKMMEN1KMT2A
SCHEMBL1179764 0.77 S1PR1 (0.34) GRM5TP53S1PR1NPC1RAB9A
SCHEMBL1178761 0.75 S1PR1 (0.52) GRM5TP53PKMMEN1KMT2A
SCHEMBL3086366 0.74 S1PR1 (0.40) TP53MEN1KMT2AS1PR1NPC1
SCHEMBL3084222 0.74 S1PR1 (0.51) TP53MEN1KMT2AS1PR1NPC1
SCHEMBL1179632 0.74 S1PR1 (0.35) TP53S1PR1NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-02-24 US claimed
EP-2262800-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-12-22 EP claimed
WO-2009109907-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-11 WO claimed
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-02-24 US disclosed
EP-2262800-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-12-22 EP disclosed
WO-2009109907-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES TYMP, DPYD, ENTPD5 GRM5 1872/4885TP53 299/4885PKM 2774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.